148 related articles for article (PubMed ID: 27606546)
1. Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.
Rabal O; Sánchez-Arias JA; Cuadrado-Tejedor M; de Miguel I; Pérez-González M; García-Barroso C; Ugarte A; Estella-Hermoso de Mendoza A; Sáez E; Espelosin M; Ursua S; Haizhong T; Wei W; Musheng X; Garcia-Osta A; Oyarzabal J
J Med Chem; 2016 Oct; 59(19):8967-9004. PubMed ID: 27606546
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
Rabal O; Sánchez-Arias JA; Cuadrado-Tejedor M; de Miguel I; Pérez-González M; García-Barroso C; Ugarte A; Estella-Hermoso de Mendoza A; Sáez E; Espelosin M; Ursua S; Haizhong T; Wei W; Musheng X; Garcia-Osta A; Oyarzabal J
Eur J Med Chem; 2018 Apr; 150():506-524. PubMed ID: 29549837
[TBL] [Abstract][Full Text] [Related]
3. Discovery of in Vivo Chemical Probes for Treating Alzheimer's Disease: Dual Phosphodiesterase 5 (PDE5) and Class I Histone Deacetylase Selective Inhibitors.
Rabal O; Sánchez-Arias JA; Cuadrado-Tejedor M; de Miguel I; Pérez-González M; García-Barroso C; Ugarte A; Estella-Hermoso de Mendoza A; Sáez E; Espelosin M; Ursua S; Haizhong T; Wei W; Musheng X; Garcia-Osta A; Oyarzabal J
ACS Chem Neurosci; 2019 Mar; 10(3):1765-1782. PubMed ID: 30525452
[TBL] [Abstract][Full Text] [Related]
4. Impact of Scaffold Exploration on Novel Dual-Acting Histone Deacetylases and Phosphodiesterase 5 Inhibitors for the Treatment of Alzheimer's Disease.
Sánchez-Arias JA; Rabal O; Cuadrado-Tejedor M; de Miguel I; Pérez-González M; Ugarte A; Sáez E; Espelosin M; Ursua S; Haizhong T; Wei W; Musheng X; Garcia-Osta A; Oyarzabal J
ACS Chem Neurosci; 2017 Mar; 8(3):638-661. PubMed ID: 27936591
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis, and Biological Evaluation of Orally Available First-Generation Dual-Target Selective Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5) for the Treatment of Alzheimer's Disease.
Mao F; Wang H; Ni W; Zheng X; Wang M; Bao K; Ling D; Li X; Xu Y; Zhang H; Li J
ACS Chem Neurosci; 2018 Feb; 9(2):328-345. PubMed ID: 29068218
[TBL] [Abstract][Full Text] [Related]
6. A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice.
Cuadrado-Tejedor M; Garcia-Barroso C; Sánchez-Arias JA; Rabal O; Pérez-González M; Mederos S; Ugarte A; Franco R; Segura V; Perea G; Oyarzabal J; Garcia-Osta A
Neuropsychopharmacology; 2017 Jan; 42(2):524-539. PubMed ID: 27550730
[TBL] [Abstract][Full Text] [Related]
7. Extending the use of tadalafil scaffold: Development of novel selective phosphodiesterase 5 inhibitors and histone deacetylase inhibitors.
ElHady AK; Shih SP; Chen YC; Liu YC; Ahmed NS; Keeton AB; Piazza GA; Engel M; Abadi AH; Abdel-Halim M
Bioorg Chem; 2020 May; 98():103742. PubMed ID: 32199305
[TBL] [Abstract][Full Text] [Related]
8. Multitarget Approach for the Treatment of Alzheimer's Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles.
Rabal O; Sánchez-Arias JA; Cuadrado-Tejedor M; de Miguel I; Pérez-González M; García-Barroso C; Ugarte A; Estella-Hermoso de Mendoza A; Sáez E; Espelosin M; Ursua S; Tan H; Wu W; Xu M; Pineda-Lucena A; Garcia-Osta A; Oyarzabal J
ACS Chem Neurosci; 2019 Sep; 10(9):4076-4101. PubMed ID: 31441641
[TBL] [Abstract][Full Text] [Related]
9. Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease.
Zuccarello E; Acquarone E; Calcagno E; Argyrousi EK; Deng SX; Landry DW; Arancio O; Fiorito J
Biochem Pharmacol; 2020 Jun; 176():113818. PubMed ID: 31978378
[TBL] [Abstract][Full Text] [Related]
10. Novel PDE5 inhibitors derived from rutaecarpine for the treatment of Alzheimer's disease.
Huang XF; Dong YH; Wang JH; Ke HM; Song GQ; Xu DF
Bioorg Med Chem Lett; 2020 May; 30(9):127097. PubMed ID: 32171616
[TBL] [Abstract][Full Text] [Related]
11. Novel Tadalafil Derivatives Ameliorates Scopolamine-Induced Cognitive Impairment in Mice via Inhibition of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5).
Ni W; Wang H; Li X; Zheng X; Wang M; Zhang J; Gong Q; Ling D; Mao F; Zhang H; Li J
ACS Chem Neurosci; 2018 Jul; 9(7):1625-1636. PubMed ID: 29616790
[TBL] [Abstract][Full Text] [Related]
12. Histone Deacetylase Inhibitors as Multitarget Ligands: New Players in Alzheimer's Disease Drug Discovery?
De Simone A; Milelli A
ChemMedChem; 2019 Jun; 14(11):1067-1073. PubMed ID: 30958639
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of dual-function inhibitors targeting NMDAR and HDAC for Alzheimer's disease.
He F; Ran Y; Li X; Wang D; Zhang Q; Lv J; Yu C; Qu Y; Zhang X; Xu A; Wei C; Chou CJ; Wu J
Bioorg Chem; 2020 Oct; 103():104109. PubMed ID: 32768741
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.
Bürli RW; Luckhurst CA; Aziz O; Matthews KL; Yates D; Lyons KA; Beconi M; McAllister G; Breccia P; Stott AJ; Penrose SD; Wall M; Lamers M; Leonard P; Müller I; Richardson CM; Jarvis R; Stones L; Hughes S; Wishart G; Haughan AF; O'Connell C; Mead T; McNeil H; Vann J; Mangette J; Maillard M; Beaumont V; Munoz-Sanjuan I; Dominguez C
J Med Chem; 2013 Dec; 56(24):9934-54. PubMed ID: 24261862
[TBL] [Abstract][Full Text] [Related]
15. Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD.
García-Barroso C; Ricobaraza A; Pascual-Lucas M; Unceta N; Rico AJ; Goicolea MA; Sallés J; Lanciego JL; Oyarzabal J; Franco R; Cuadrado-Tejedor M; García-Osta A
Neuropharmacology; 2013 Jan; 64():114-23. PubMed ID: 22776546
[TBL] [Abstract][Full Text] [Related]
16. First in Class Dual Non-ATP-Competitive Glycogen Synthase Kinase 3β/Histone Deacetylase Inhibitors as a Potential Therapeutic to Treat Alzheimer's Disease.
Santini A; Tassinari E; Poeta E; Loi M; Ciani E; Trazzi S; Piccarducci R; Daniele S; Martini C; Pagliarani B; Tarozzi A; Bersani M; Spyrakis F; Danková D; Olsen CA; Soldati R; Tumiatti V; Montanari S; De Simone A; Milelli A
ACS Chem Neurosci; 2024 Jun; 15(11):2099-2111. PubMed ID: 38747979
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and structure-activity relationship of functionalized tetrahydro-β-carboline derivatives as novel PDE5 inhibitors.
Ahmed NS; Gary BD; Tinsley HN; Piazza GA; Laufer S; Abadi AH
Arch Pharm (Weinheim); 2011 Mar; 344(3):149-57. PubMed ID: 21384413
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of 2-aminobenzanilide derivatives as potent and selective HDAC inhibitors.
Stolfa DA; Stefanachi A; Gajer JM; Nebbioso A; Altucci L; Cellamare S; Jung M; Carotti A
ChemMedChem; 2012 Jul; 7(7):1256-66. PubMed ID: 22628266
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of dual acetylcholinesterase and phosphodiesterase 5A inhibitors in treatment for Alzheimer's disease.
Zhou LY; Zhu Y; Jiang YR; Zhao XJ; Guo D
Bioorg Med Chem Lett; 2017 Sep; 27(17):4180-4184. PubMed ID: 28751142
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment.
Chen JB; Chern TR; Wei TT; Chen CC; Lin JH; Fang JM
J Med Chem; 2013 May; 56(9):3645-55. PubMed ID: 23570542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
